Sargent Bickham Lagudis’s Denali Therapeutics DNLI Stock Holding History

Sargent Bickham Lagudis’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-165	Closed	-$8K	–	968
2021 Q3	$8K	Hold	165	–	–	﹤0.01%	748
2021 Q2	$13K	Hold	165	–	–	﹤0.01%	670
2021 Q1	$9K	Hold	165	–	–	﹤0.01%	714
2020 Q4	$14K	Hold	165	–	–	﹤0.01%	607
2020 Q3	$6K	Sell	165 -22	-12%	-$663	﹤0.01%	640
2020 Q2	$5K	Buy	+187	New	+$4.4K	﹤0.01%	640

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Sargent Bickham Lagudis's DNLI Position: Q4 2021 in Review

Sargent Bickham Lagudis sold out of Denali Therapeutics (DNLI) in Q4 2021, closing a stake of 165 shares — an estimated $8K sold.

Sargent Bickham Lagudis first reported a position in DNLI in Q2 2020 and held it in 6 quarters. The position peaked at $14K in Q4 2020. 213 funds tracked by Wall St. Rank hold DNLI as of Q4 2021.

Sargent Bickham Lagudis reported no remaining Denali Therapeutics position as of Q4 2021 after selling out during the quarter.
Sargent Bickham Lagudis sold 165 Denali Therapeutics shares in Q4 2021, an estimated $8K.
Sargent Bickham Lagudis first reported a position in Denali Therapeutics in Q2 2020 and held it in 6 quarters.
Sargent Bickham Lagudis's Denali Therapeutics position peaked at $14K in Q4 2020.
213 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2021, filed 18 Jan 2022.